Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

FDA clears Blueprint’s $32k-per-month GI cancer drug

FDA clears Blueprint’s $32k-per-month GI cancer drug imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent.

Bayer extends alliance with Evotec in women’s health

Bayer extends alliance with Evotec in women’s health Bayer and Evotec will both contribute drug targets to the alliance as well as other technology platforms, and will jointly develop drugs arising from it. ... It’s still listed as an active programme in Bayer’s latest pipeline update.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Marketing Capability Development

by Bayer Russia with support from Ashfield Insight &Performance. Ashfield Insight &Performance (AI&P) was approached by Bayer Russia to upskill the marketing capabilities of the product managers, to enable them ... Marketing Capability Development - by

EMAcademy

Marketing Capability Development - by Bayer Russia with support from Ashfield Insight &Performance.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics